SironRX is venture-backed biotechnology company developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote wound repair and prevent scarring of dermal wounds. The lead product, JVS100 is a clinically tested product that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is produced by the body in response to tissue injury and activates natural repair processes to prevent cell death and recruit stem cells to the damaged organ. For its first clinical indication the SironRx will evaluate the safety and efficacy of JVS-100 in the treatment of post-surgical wounds.
SironRX will initiate a Phase II clinical trial in 2011 to evaluate the efficacy and safety of SRX-100 treatment in accelerating wound repair and preventing scarring. Clinical studies with SRX-100 have demonstrated the drug is well tolerated and safe. SironRX is raising funds to complete a Phase II clinical trial in 2012